Understanding of the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments to expenditure to tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, the majority of drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.
The 2007-09 and 2011 Action Plans of the National Strategy for Prevention of Drug Dependency 2004-12 had annual associated budgets. An evaluation of the national strategy pointed out a limited budget as one of its shortcomings. The National Health Plan 2009-20 has not yet presented its associated budget. Estimates for labelled drug-related public expenditures have, however, been published since 2007. The methodology used to collect and estimate these expenditures cannot be assessed, but results are comparable over time (with the exception of 2012).
The 2011 data indicate that labelled drug-related expenditures represented 0.023 % of gross domestic product (GDP). Between 2007 and 2011, labelled expenditures were classified as demand reduction activities (about 76 %) and supply reduction activities (about 24 %).
The available data indicate that between 2007 and 2010 labelled expenditures fell from 0.027 % of GDP to 0.021 %. This decrease is attributed to the public austerity measures following the economic recession of 2008. The largest decrease was reported in supply reduction until 2009. In 2010, labelled expenditures in supply reduction registered a nominal increase, while expenditures in demand reduction activities declined further. In 2011, labelled expenditures increased to 0.023 % of GDP. Comprehensive and comparable data are not available beyond 2013.
In 2011, labelled public expenditure was 0.023 % of gross domestic product